Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs like...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Report on the 29th annual meeting of the kidney transplantation working group of the German Society of Urology in Marburg 2023].

Urologie (Heidelberg, Germany)·2024
Same author

Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial.

Trials·2023
Same author

[Imaging in metastatic prostate cancer].

Der Urologe. Ausg. A·2021
Same author

[Minimally invasive surgery for aggressive tumors].

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020

Related Experiment Video

Updated: May 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

[When should systemic chemotherapy be used for urinary bladder carcinoma?].

C-H Ohlmann1, M Stöckle

  • 1Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstraße 1, 66421 Homburg/Saar, Deutschland. Carsten.Ohlmann@uks.eu

Der Urologe. Ausg. A
|October 21, 2011
PubMed
Summary

Perioperative chemotherapy for bladder cancer remains debated, with limited evidence for adjuvant use. However, neoadjuvant chemotherapy may improve operability for advanced tumors, and node-positive patients might benefit from adjuvant treatment.

Related Experiment Videos

Last Updated: May 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

  • Uro-oncology
  • Medical oncology
  • Surgical oncology

Background:

  • The role of perioperative chemotherapy in urinary bladder carcinoma lacks high-grade recommendations due to stagnant clinical trial evidence over the past decade.
  • While neoadjuvant chemotherapy can downsize locally advanced tumors, improving surgical operability, the impact of surgical quality on recurrence risk and prognosis is significant.
  • Retrospective analyses suggest potential benefits of adjuvant chemotherapy, particularly for node-positive bladder cancer patients undergoing radical cystectomy.

Purpose of the Study:

  • To review the current evidence and ongoing debate surrounding perioperative chemotherapy for bladder cancer.
  • To highlight the specific considerations for neoadjuvant and adjuvant chemotherapy in the context of radical cystectomy.
  • To discuss the established chemotherapeutic agents and their roles in metastatic and second-line treatment settings.

Main Methods:

  • Review of existing clinical trial data and retrospective studies on perioperative chemotherapy for bladder cancer.
  • Analysis of factors influencing treatment outcomes, including tumor downstaging and surgical quality.
  • Evaluation of current standards of care for metastatic and recurrent bladder cancer.

Main Results:

  • Current guidelines offer limited high-grade recommendations for perioperative chemotherapy, especially adjuvant chemotherapy.
  • Neoadjuvant chemotherapy can facilitate better surgical outcomes by reducing tumor size.
  • Node-positive patients undergoing radical cystectomy may experience improved outcomes with adjuvant chemotherapy.

Conclusions:

  • The optimal use of perioperative chemotherapy in bladder cancer requires further investigation, balancing oncological benefits with surgical considerations.
  • Gemcitabine plus cisplatin remains the standard for metastatic disease, while vinflunin is established for second-line therapy.
  • Future clinical trials should consider these standards as comparators for evaluating novel treatment strategies.